Successful Treatment of Acute Lymphoblastic Leukemia With L-Asparaginase-Induced Intracranial Hemorrhage to Activated Recombinant Factor Viia in a Child

Uçar, Canan; Çalışkan, Ümran

doi:10.1080/08880010600631987

Cited by 3 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been used for the management of pulmonary hemorrhage [15], massive hemoptysis [16], bleeding from various sites after bone marrow transplantation [17][18][19][20], upper GI bleeding [21][22][23][24], Hickman line insertion [25], intestinal hemorrhage [26], intracranial hemorrhage [27], uterine bleeding [28], femoral artery bleeding after central venous catheter insertion [29], and alltransretinoic acidinduced pulmonary bleeding [30].…”

Section: Discussionmentioning

confidence: 99%

Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII

et al. 2009

View full text Add to dashboard Cite

Hemorrhage is a frequent complication in patients with acute leukemias as a result of chemotherapy-induced myelosuppression. Gastrointestinal bleeding in thrombocytopenic patients carries a high mortality. Patients are generally managed with red blood cell, platelet suspensions, and fresh frozen plasma; and sometimes with pharmacologic and endoscopic interventions. If these therapeutic measures fail, patients might be treated with hemostatic drugs, one example of which is recombinant activated factor VII (rFVIIa). This drug is recommended for all kinds of bleeding in hemophiliacs with inhibitors; it is also being used for the treatment of bleeding in thrombocytopenia and platelet function disorders. We present our 44-year-old female patient who had gastrointestinal system bleeding after remission induction therapy for acute myeloid leukemia. Thrombocytopenia was refractory to apheresis platelets; and gastrointestinal bleeding could be controlled only after the administration of a single dose (35 microg/kg, total dose 2.4 mg) of rFVIIa. Our experience indicates that rFVIIa might be a novel treatment alternative in massive bleeding in leukemic patients with thrombocytopenia or platelet function disorders.

show abstract

Section: Discussionmentioning

confidence: 99%

Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Recombinant activated factor VII (rFVIIa) has been used in the management of life-threatening hemorrhage in patients with thrombocytopenia in association with hematologic malignancy. 5,34 About 50% of patients reported by Brenner et al 5 who received rFVIIa were children (< 18 years) with hematologic malignancy. Additional evaluation of this agent in the pediatric patient needs to be investigated in controlled clinical trials.…”

Section: Clinical Features Of Bleeding Manifestations In Children Witmentioning

confidence: 99%

Hemorrhagic Complications in Pediatric Hematologic Malignancies

Athale

Chan

2007

Semin Thromb Hemost

View full text Add to dashboard Cite

Hematologic malignancies account for almost 40% of all cancers in children. Hemorrhage is the most common cause of early death in children with leukemia. Furthermore, major bleeding episodes lead to shorter survival and increased resource use. Potential risk factors for bleeding include hyperleukocytosis, immunophenotype of leukemia (especially acute promyelocytic leukemia), thrombocytopenia, and associated infections. Successful management of a bleeding episode is dependent on prompt identification of a child at high risk for bleeding, and should be directed at the replacement of blood products as well as to the aggressive therapy for underlying risk factors. Although in recent years there is a favorable decline in the hemorrhage-related mortality, the overall prevalence and the extent of morbidity posed by this potentially fatal complication, including disease outcome in children with hematologic malignancy, is largely unknown. In addition, there are no evidence-based guidelines for prophylactic blood or blood product transfusions. Prospective studies are required to define the epidemiology and risk factors predisposing children with hematologic malignancy to bleeding and to develop management guidelines.

show abstract

The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review

Franchini

Veneri

Lippi

2007

Bone Marrow Transplant

View full text Add to dashboard Cite

Successful Treatment of Acute Lymphoblastic Leukemia With L-Asparaginase-Induced Intracranial Hemorrhage to Activated Recombinant Factor Viia in a Child

Cited by 3 publications

References 19 publications

Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII

Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII

Hemorrhagic Complications in Pediatric Hematologic Malignancies

The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review

Contact Info

Product

Resources

About